Cargando…

Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai

BACKGROUND: It is estimated that at present there are over 10 million rare disease patients in China. Recently an increased focus from policy perspective has been placed on rare diseases management. Improved disease definitions and the releases of local and national rare disease lists are some of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Xiaoshu, Yang, Hui, Genchev, Georgi Z., Lu, Hui, Yu, Guangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806581/
https://www.ncbi.nlm.nih.gov/pubmed/31640704
http://dx.doi.org/10.1186/s13023-019-1168-4
_version_ 1783461665665187840
author Cai, Xiaoshu
Yang, Hui
Genchev, Georgi Z.
Lu, Hui
Yu, Guangjun
author_facet Cai, Xiaoshu
Yang, Hui
Genchev, Georgi Z.
Lu, Hui
Yu, Guangjun
author_sort Cai, Xiaoshu
collection PubMed
description BACKGROUND: It is estimated that at present there are over 10 million rare disease patients in China. Recently an increased focus from policy perspective has been placed on rare diseases management. Improved disease definitions and the releases of local and national rare disease lists are some of the steps taken already. Despite these developments, few Chinese rare disease-related epidemiology and economic studies exist, thus hindering assessment of the true burden of rare diseases. For a rare disease with an effective treatment, this is a particularly important aspect due to the often-high cost associated. OBJECTIVE: The goal of this study is to address the data scarcity on the subject of rare diseases economic impact in China. We aim to address an existing knowledge gap and to provide a timely analysis of the economic burden of 23 rare diseases in Shanghai, China. METHODS: We utilized the data from the Health Information Exchange system of Shanghai and employed statistical modeling to analyze the economic burden of rare diseases with an effective treatment in Shanghai. RESULTS: First, we described the actual direct medical expenditure and analyzed its associated factors. Second, we found age, disease type, number of complications, and payment type were significantly associated with rare disease medical direct costs. Third, a generalized linear model was employed to estimate the annual direct cost. The mean direct medical cost was estimated as ¥9588 (US$1521) for inpatients and ¥1060 (US$168) for outpatients, and was over ¥15 million (~US$2.4 million) per year overall. CONCLUSION: Our study is one of the first quantifying the economic burden of an extensive set of rare diseases in Shanghai and China. Our results can serve to inform healthcare-focused policy making, contribute to the increase of public awareness, and incentivize development of rare-disease strategies and treatments specific to the Chinese context. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1168-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6806581
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68065812019-10-28 Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai Cai, Xiaoshu Yang, Hui Genchev, Georgi Z. Lu, Hui Yu, Guangjun Orphanet J Rare Dis Research BACKGROUND: It is estimated that at present there are over 10 million rare disease patients in China. Recently an increased focus from policy perspective has been placed on rare diseases management. Improved disease definitions and the releases of local and national rare disease lists are some of the steps taken already. Despite these developments, few Chinese rare disease-related epidemiology and economic studies exist, thus hindering assessment of the true burden of rare diseases. For a rare disease with an effective treatment, this is a particularly important aspect due to the often-high cost associated. OBJECTIVE: The goal of this study is to address the data scarcity on the subject of rare diseases economic impact in China. We aim to address an existing knowledge gap and to provide a timely analysis of the economic burden of 23 rare diseases in Shanghai, China. METHODS: We utilized the data from the Health Information Exchange system of Shanghai and employed statistical modeling to analyze the economic burden of rare diseases with an effective treatment in Shanghai. RESULTS: First, we described the actual direct medical expenditure and analyzed its associated factors. Second, we found age, disease type, number of complications, and payment type were significantly associated with rare disease medical direct costs. Third, a generalized linear model was employed to estimate the annual direct cost. The mean direct medical cost was estimated as ¥9588 (US$1521) for inpatients and ¥1060 (US$168) for outpatients, and was over ¥15 million (~US$2.4 million) per year overall. CONCLUSION: Our study is one of the first quantifying the economic burden of an extensive set of rare diseases in Shanghai and China. Our results can serve to inform healthcare-focused policy making, contribute to the increase of public awareness, and incentivize development of rare-disease strategies and treatments specific to the Chinese context. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1168-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-10-22 /pmc/articles/PMC6806581/ /pubmed/31640704 http://dx.doi.org/10.1186/s13023-019-1168-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cai, Xiaoshu
Yang, Hui
Genchev, Georgi Z.
Lu, Hui
Yu, Guangjun
Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title_full Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title_fullStr Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title_full_unstemmed Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title_short Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai
title_sort analysis of economic burden and its associated factors of twenty-three rare diseases in shanghai
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806581/
https://www.ncbi.nlm.nih.gov/pubmed/31640704
http://dx.doi.org/10.1186/s13023-019-1168-4
work_keys_str_mv AT caixiaoshu analysisofeconomicburdenanditsassociatedfactorsoftwentythreerarediseasesinshanghai
AT yanghui analysisofeconomicburdenanditsassociatedfactorsoftwentythreerarediseasesinshanghai
AT genchevgeorgiz analysisofeconomicburdenanditsassociatedfactorsoftwentythreerarediseasesinshanghai
AT luhui analysisofeconomicburdenanditsassociatedfactorsoftwentythreerarediseasesinshanghai
AT yuguangjun analysisofeconomicburdenanditsassociatedfactorsoftwentythreerarediseasesinshanghai